Press release
Advanced Endometrial Cancer Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Advanced Endometrial Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Advanced Endometrial Cancer Pipeline Report
* In August 2025, Iovance Biotherapeutics Inc . announced a study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 (PD-1)/programmed death ligand 1 (PD-L1) agent in a recurrent or advanced setting, either sequentially or in combination.
* In August 2025, Seagen conducted a clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. In the first part of the study, participants must have tumors that have a marker called HER2.
* In August 2025, Genmab announced a Phase 1/2 study of GEN1107, a protein tyrosine K 7 (PTK7) targeted antibody-drug conjugate (ADC), to evaluate the safety, tolerability, PK, and antitumor activity of GEN1107 in participants with advanced solid tumors, including ovarian cancer, endometrial cancer, triple negative breast cancer, non-small cell lung cancer, gastroesophageal cancer, and urothelial cancer. This study consists of 2 parts, Part A: Dose Escalation and Dose Level Expansion and Part B: Tumor Specific Expansion.
* In August 2025, 858 Therapeutics Inc . conducted a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
* In August 2025, Fusion Pharmaceuticals Inc. announced a study consists of a Phase 1 portion and a Phase 2 portion. Phase 1 includes the following cohorts: Single dose-ascending cohorts and Multi- dose ascending cohorts of [225Ac]-FPI-1434 and Multi- dose ascending cohorts evaluating administration of FPI-1175 (cold antibody), followed by, [225Ac]-FPI-1434 (cold + hot), with cycles repeating every 42 days. And Cold Antibody Sub-study evaluating administration of ascending doses of FPI-1175 followed by [111In]-FPI-1547.
* DelveInsight's Advanced Endometrial Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Advanced Endometrial Cancer treatment.
* The leading Advanced Endometrial Cancer Companies such as Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics , and others.
* Promising Advanced Endometrial Cancer pipeline therapies such as Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
Discover how the Advanced Endometrial Cancer treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ Advanced Endometrial Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Endometrial Cancer Emerging Drugs
* Retifanlimab: Incyte Corporation
Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer and SCAC.
* Trastuzumab duocarmazine (SYD985): Byondis
The most advanced compound in the company's pipeline is trastuzumab duocarmazine (US non-proprietary name [vic-]trastuzumab duocarmazine). This investigational anti-HER2 ADC, targets a broad range of HER2-expressing cancers such as (metastatic) breast, gastric, bladder (urothelial) and uterine (endometrial) cancer. Trastuzumab duocarmazine could be used in patients where other (anti-HER2) treatments have failed, reflecting our philosophy of developing new, innovative medicines for relentless cancers. Trastuzumab duocarmazine is Byondis' frontrunner ADC. The antibody, trastuzumab, can bind to a specific protein, HER2 (Human Epidermal growth factor Receptor 2) on the cell surface of tumor cells in many different tumor types. The linker-drug in trastuzumab duocarmazine is vc-seco-DUBA.
The Advanced Endometrial Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Endometrial Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Endometrial Cancer Treatment.
* Advanced Endometrial Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Advanced Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Endometrial Cancer market.
Get a detailed analysis of the latest innovations in the Advanced Endometrial Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Advanced Endometrial Cancer Unmet Needs [https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Endometrial Cancer Companies
Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Advanced Endometrial Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Download DelveInsight's latest report to gain strategic insights into upcoming Advanced Endometrial Cancer Therapies and key Advanced Endometrial Cancer Developments @ Advanced Endometrial Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Advanced Endometrial Cancer Pipeline Report
* Coverage- Global
* Advanced Endometrial Cancer Companies- Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics , and others.
* Advanced Endometrial Cancer pipeline therapies- Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
* Advanced Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Advanced Endometrial Cancer drug development? Find out in DelveInsight's exclusive pipeline Report-access it now! @ Advanced Endometrial Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/advanced-endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Advanced Endometrial Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Endometrial Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Selinexor: Karyopharm Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Retifanlimab: Incyte Corporation
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Alsevalimab: Five Prime Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Endometrial Cancer Key Companies
* Advanced Endometrial Cancer Key Products
* Advanced Endometrial Cancer- Unmet Needs
* Advanced Endometrial Cancer- Market Drivers and Barriers
* Advanced Endometrial Cancer- Future Perspectives and Conclusion
* Advanced Endometrial Cancer Analyst Views
* Advanced Endometrial Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-endometrial-cancer-pipeline-outlook-report-2025-key-25-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-endometrial-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Endometrial Cancer Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4142773 • Views: …
More Releases from ABNewswire
Stellar Scientific's Drosophila Incubators: The Perfect Solution for Temperature …
Stellar Scientific's Drosophila incubators provide precise temperature control and stable environments for Drosophila melanogaster research. With customizable settings, flexible storage, and energy-efficient design, they support diverse experiments in genetics, development, and neurobiology. Durable and reliable, these incubators help researchers achieve consistent, reproducible results.
Stellar Scientific, a trusted leader in scientific equipment and laboratory solutions, is pleased to highlight its line of Drosophila incubators, designed specifically for temperature-sensitive research. Known for their…
BuyModa.net Publishes Definitive Guide on How to Buy Modafinil Online Safely and …
SAN FRANCISCO, Calif. - August 19, 2025 - Buymoda.net, a leading independent authority on Modafinil and cognitive enhancement, has released its most comprehensive guide yet for individuals seeking to buy Modafinil online. The updated resource provides detailed vendor comparisons, safety insights, and practical advice to help buyers navigate a marketplace that is often confusing and filled with misinformation.
Addressing Growing Demand for Trusted Information
Interest in Modafinil continues to rise among students,…
Redefined Restoration Brings Trusted Water Damage Relief to Chicago
Water isn't just a vital resource-it can quickly become a destructive force that damages homes, disrupts lives, and creates costly repairs. In Chicago, where seasonal storms, burst pipes, and plumbing failures are common, the need for a reliable partner in water damage restoration is greater than ever. Redefined Restoration - Chicago Water Damage Service has emerged as that trusted partner, offering rapid response, professional care, and outstanding results when disaster…
Redefined Restoration: Chicago's Trusted Answer for Water Damage Restoration
When disaster strikes a home or business-whether from a burst pipe, torrential rain, or appliance failure-people need real help, fast. That's why more Chicago residents are turning to Redefined Restoration - Chicago Water Damage Service during their most stressful moments. In a city where reliability means everything, the company has quickly become the top choice among water damage restoration companies near me and one of the most trusted water damage…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
